Answers are grounded in this paper and cite their sources.
The prolonged effects of neonatal SRIH-14 treatment on pituitary ACTH cells were investigated. Neonatal female rats were injected subcutaneously with SRIH (20 microg/100g b.w.) every 12 hours for five consecutive days (3rd-7th day of life). Groups of rats were then killed at the juvenile (16th day), peripubertal (38th day) or adult (80th day) stage. ACTH cells were visualized using the peroxidase-antiperoxidase immunocytochemical procedure. Morphometry and stereology were used to evaluate the ACTH-immunoreactive cell volume and volume density. The histological and immunocytochemical characteristics of ACTH cells in neonatally treated females were changed in all examined periods. Thus, SRIH-14 induced significant (p<0.05) decreases of ACTH cell volume in juvenile, peripubertal and adult rats by 26%, 39% and 14%, respectively, in comparison to the corresponding controls. The volume density of ACTH cells was also diminished (by 31%; p<0.05) at the juvenile stage in comparison with the corresponding controls. In peripubertal and adult rats, the volume densities of ACTH cells were somewhat lower (17% and 14%, respectively), but the decreases did not reach statistical significance. These findings suggest that neonatal treatment with SRIH-14 exerts a marked prolonged inhibitory effect on ACTH cell morphology extending to the adult period of life.
No takes yet. Share an insight, caveat, or question.
Milošević et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: